Physician profile
James Ty Lin
NPI 1184742025
$4,544.12
in general payments reported to CMS, 2019-2025
33 companies · $1,623 in 2025
The $1,623 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2021: $317 · 2022: $465 · 2023: $874 · 2024: $387 · 2025: $1,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619 · Travel and Lodging: $1,044 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.31 |
| Travel and Lodging | $1,044.16 |
| Education | $220.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $1,063.69 | 2023-2025 | Excelsius Gps, Excelsiusgps Robotic Navigation System |
| Supernus Pharmaceuticals, INC. | $628.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $486.58 | 2021-2025 | Austedo Xr, Austedo Xr |
| Mdd US Operations, LLC | $360.57 | 2022-2025 | Gocovri, Gocovri |
| Amneal Pharmaceuticals LLC | $271.69 | 2021-2025 | Crexont, Rytary |
| Cmp Pharma, INC. | $237.31 | 2023 | Norliqva |
| Tanabe Pharma America, INC. | $196.77 | 2022-2024 | |
| Ucb, INC. | $179.16 | 2022-2025 | Briviact, Rystiggo |
| Sunovion Pharmaceuticals INC. | $127.11 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $113.66 | 2021-2022 | |
| Acorda Therapeutics, INC | $108.22 | 2019 | |
| Nevro Corp. | $84.22 | 2023 | Senza |
| Scilex Pharmaceuticals INC. | $82.48 | 2023-2025 | Ztlido |
| Sumitomo Pharma America, INC. | $52.66 | 2023 | Aptiom |
| Jazz Pharmaceuticals INC. | $52.02 | 2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $48.93 | 2021 | |
| Amgen INC. | $47.27 | 2025 | Uplizna |
| Boston Scientific Corporation | $37.67 | 2024 | |
| Assertio Therapeutics, INC. | $36.13 | 2019 | |
| Radius Health, INC. | $35.00 | 2019 | |
| Lilly USA, LLC | $28.50 | 2024 | Amyvid |
| Neurocrine Biosciences, INC. | $28.22 | 2021 | |
| Pfizer INC. | $27.32 | 2021 | |
| Alexion Pharmaceuticals, INC. | $26.57 | 2025 | Ultomiris |
| Avanir Pharmaceuticals, INC. | $23.62 | 2021 | |
| Impel Pharmaceuticals INC. | $22.45 | 2022 | |
| Adamas Pharmaceuticals, INC. | $22.33 | 2021 | |
| Abbott Laboratories | $22.26 | 2019 | |
| Aquestive Therapeutics, INC. | $22.07 | 2021 | |
| Corium, LLC | $21.91 | 2022 | |
| Zyla Life Sciences, INC. | $20.01 | 2019 | |
| Horizon Therapeutics Plc | $15.39 | 2022 | |
| Cycle Pharmaceuticals INC | $13.98 | 2025 | Tascenso Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.